Articles
Page 1 of 3
-
Citation: Genetic Vaccines and Therapy 2003 1:1
-
DNA vaccines: improving expression of antigens
DNA vaccination is a relatively recent development in vaccine methodology. It is now possible to undertake a rational step-by-step approach to DNA vaccine design. Strategies may include the incorporation of im...
Citation: Genetic Vaccines and Therapy 2003 1:2 -
Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma
Allergic subjects produce relatively low amounts of IFN-γ, a pleiotropic Th-1 cytokine that downregulates Th2-associated airway inflammation and hyperresponsiveness (AHR), the hallmarks of allergic asthma. Ade...
Citation: Genetic Vaccines and Therapy 2003 1:3 -
Novel non-viral method for transfection of primary leukemia cells and cell lines
Tumor cells such as leukemia and lymphoma cells are possible targets for gene therapy. However, previously leukemia and lymphoma cells have been demonstrated to be resistant to most of non-viral gene transfer ...
Citation: Genetic Vaccines and Therapy 2004 2:1 -
Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation
The clinical application of monoclonal antibodies (mAbs) potentially concerns a wide range of diseases including, among others, viral infections, cancer and autoimmune diseases. Although intravenous infusion a...
Citation: Genetic Vaccines and Therapy 2004 2:2 -
Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescue
Leber's congenital amaurosis (LCA) is a severe form of retinal dystrophy. Mutations in the RPE65 gene, which is abundantly expressed in retinal pigment epithelial (RPE) cells, account for approximately 10–15% ...
Citation: Genetic Vaccines and Therapy 2004 2:3 -
Long term physiologic modification using rAAV in utero gene-therapy
Transfer of genes in utero via the amniotic fluid was shown previously with recombinant adeno-associated viruses (rAAV) to be highly efficient. Expression for over one year was demonstrated using reporter genes. ...
Citation: Genetic Vaccines and Therapy 2004 2:4 -
The recombinant adeno-associated virus vector (rAAV2)-mediated apolipoprotein B mRNA-specific hammerhead ribozyme: a self-complementary AAV2 vector improves the gene expression
In humans, overproduction of apolipoprotein B (apoB) is positively associated with premature coronary artery diseases. To reduce the levels of apoB mRNA, we have designed an apoB mRNA-specific hammerhead riboz...
Citation: Genetic Vaccines and Therapy 2004 2:5 -
The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events
Although lentiviral vectors have been widely used for in vitro and in vivo gene therapy researches, there have been few studies systematically examining various conditions that may affect the determination of the...
Citation: Genetic Vaccines and Therapy 2004 2:6 -
A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivoimaging of gene therapy in malignant glioma
Suicide gene therapy employing the prodrug activating system Herpes simplex virus type 1 thymidine kinase (HSV-TK)/ ganciclovir (GCV) has proven to be effective in killing experimental brain tumors. In contras...
Citation: Genetic Vaccines and Therapy 2004 2:7 -
Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery
The need for safe and effective treatment of dengue virus (DEN), a class A agent that causes dengue hemorrhagic fever/dengue shock syndrome, has been a critical global priority. An effective vaccine for DEN is...
Citation: Genetic Vaccines and Therapy 2004 2:8 -
The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery
Retroviral vector-mediated gene transfer has been central to the development of gene therapy. Retroviruses have several distinct advantages over other vectors, especially when permanent gene transfer is the pr...
Citation: Genetic Vaccines and Therapy 2004 2:9 -
Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 ± IL-15
A vaccine that elicits durable, powerful anti-HIV immunity remains an elusive goal. In these studies we tested whether multiple treatments with viral vector-delivered HIV envelope antigen (gp120), with and wit...
Citation: Genetic Vaccines and Therapy 2004 2:10 -
Comparison of bovine leukemia virus (BLV) and CMV promoter-driven reporter gene expression in BLV-infected and non-infected cells
Viral promoters are used in mammalian expression vectors because they generally have strong activity in a wide variety of cells of differing tissues and species.
Citation: Genetic Vaccines and Therapy 2004 2:11 -
Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer
Modulation of the immune system by genetically modified immunological effector cells is of potential therapeutic value in the treatment of malignancies. Interleukin-2 (IL-2) is a crucial cytokine which induces...
Citation: Genetic Vaccines and Therapy 2004 2:12 -
Skipping the co-expression problem: the new 2A "CHYSEL" technology
The rapid progress in the field of genomics is increasing our knowledge of multi-gene diseases. However, any realistic hope of gene therapy treatment for those diseases needs first to address the problem of co...
Citation: Genetic Vaccines and Therapy 2004 2:13 -
Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector
The establishment of efficient gene delivery to target human tissue is a major obstacle for transition of gene therapy from the pre-clinical phases to the clinic. The poor long-term patency rates for coronary ...
Citation: Genetic Vaccines and Therapy 2004 2:14 -
Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC
Modulation of the immune system by genetically modified lymphoma cell vaccines is of potential therapeutic value in the treatment of B cell lymphoma. However, the anti-tumor effect of any single immunogene tra...
Citation: Genetic Vaccines and Therapy 2004 2:15 -
In vivogene targeting of IL-3 into immature hematopoietic cells through CD117 receptor mediated antibody gene delivery
Targeted gene transfection remains a crucial issue to permit the real development of genetic therapy. As such, in vivo targeted transfection of specific subsets of hematopoietic stem cells might help to sustain h...
Citation: Genetic Vaccines and Therapy 2004 2:16 -
DNA vaccines: designing strategies against parasitic infections
The complexity of parasitic infections requires novel approaches to vaccine design. The versatility of DNA vaccination provides new perspectives. This review discusses the use of prime-boost immunizations, gen...
Citation: Genetic Vaccines and Therapy 2004 2:17 -
Human cytomegalovirus plasmid-based amplicon vector system for gene therapy
We have constructed and evaluated the utility of a helper-dependent virus vector system that is derived from Human Cytomegalovirus (HCMV). This vector is based on the herpes simplex virus (HSV) amplicon system...
Citation: Genetic Vaccines and Therapy 2005 3:1 -
Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells
The aim of this study was to determine the optimal non-viral transfection method for use in human smooth muscle cells (SMC) and endothelial cells (EC).
Citation: Genetic Vaccines and Therapy 2005 3:2 -
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax
Previously, antigens expressed from DNA vaccines have been fused to the VP22 protein from Herpes Simplex Virus type I in order to improve efficacy. However, the immune enhancing mechanism of VP22 is poorly und...
Citation: Genetic Vaccines and Therapy 2005 3:3 -
Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines
The production of cell-based cancer vaccines by gene vectors encoding proteins that stimulate the immune system has advanced rapidly in model systems. We sought to develop non-viral transfection methods that c...
Citation: Genetic Vaccines and Therapy 2005 3:4 -
Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer
Lung cancer has emerged as a leading cause of cancer death in the world. Non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Current therapies are ineffective, thus new approaches are n...
Citation: Genetic Vaccines and Therapy 2005 3:5 -
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas
Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients w...
Citation: Genetic Vaccines and Therapy 2005 3:6 -
A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses
Several studies have shown that cell-mediated immune responses play a crucial role in controlling viral replication. As such, a candidate SARS vaccine should elicit broad CD8+ T-cell immune responses. Several ...
Citation: Genetic Vaccines and Therapy 2005 3:7 -
A trial of somatic gene targeting in vivo with an adenovirus vector
Gene targeting in vivo provides a potentially powerful method for gene analysis and gene therapy. In order to sensitively detect and accurately measure designed sequence changes, we have used a transgenic mouse s...
Citation: Genetic Vaccines and Therapy 2005 3:8 -
Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery
In order to assess a new strategy of DNA vaccine for a more complete understanding of its action in immune response, it is important to determine the in vivo biodistribution fate and antigen expression. In previo...
Citation: Genetic Vaccines and Therapy 2006 4:1 -
Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine
Published data indicate that formulation of pDNA with cationic lipids could greatly enhance the response to a pDNA vaccine in larger mammals. The present work tested the influence of several pDNA:cationic lipi...
Citation: Genetic Vaccines and Therapy 2006 4:2 -
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
Duchenne muscular dystrophy is a fatal genetic disorder caused by dystrophin gene mutations that result in premature termination of translation and the absence of functional protein. Despite the primary dystro...
Citation: Genetic Vaccines and Therapy 2006 4:3 -
Characterization of the ribonuclease activity on the skin surface
The rapid degradation of ribonucleic acids (RNA) by ubiquitous ribonucleases limits the efficacy of new therapies based on RNA molecules. Therefore, our aim was to characterize the natural ribonuclease activit...
Citation: Genetic Vaccines and Therapy 2006 4:4 -
Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA
Mucopolysaccharidosis type IIIA (MPS IIIA) is the most common of the mucopolysaccharidoses. The disease is caused by a deficiency of the lysosomal enzyme sulphamidase and results in the storage of the glycosam...
Citation: Genetic Vaccines and Therapy 2007 5:1 -
Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs
The great challenges for researchers working in the field of vaccinology are optimizing DNA vaccines for use in humans or large animals and creating effective single-dose vaccines using appropriated controlled...
Citation: Genetic Vaccines and Therapy 2007 5:2 -
Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120
For reasons of efficiency Escherichia coli is used today as the microbial factory for production of plasmid DNA vaccines. To avoid hazardous antibiotic resistance genes and endotoxins from plasmid systems used no...
Citation: Genetic Vaccines and Therapy 2007 5:3 -
Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene
Respiratory syncytial virus (RSV) causes severe bronchiolitis and is a risk factor for asthma. Since there is no commercially available vaccine against RSV, a short interfering RNA against the RSV-NS1gene (siN...
Citation: Genetic Vaccines and Therapy 2007 5:4 -
Is gene therapy a good therapeutic approach for HIV-positive patients?
Despite advances and options available in gene therapy for HIV-1 infection, its application in the clinical setting has been challenging. Although published data from HIV-1 clinical trials show safety and proo...
Citation: Genetic Vaccines and Therapy 2007 5:5 -
DNA vaccine constructs against enterovirus 71 elicit immune response in mice
Enterovirus 71 (EV71) is a major causative viral agent responsible for large outbreaks of hand, foot and mouth disease (HFMD), a common rash illness in children and infants. There is no effective antiviral tre...
Citation: Genetic Vaccines and Therapy 2007 5:6 -
Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming
Vaccines are considered by many to be one of the most successful medical interventions against infectious diseases. But many significant obstacles remain, such as optimizing DNA vaccines for use in humans or l...
Citation: Genetic Vaccines and Therapy 2007 5:7 -
Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivodendritic cells and T lymphocytes
Safe and efficient vector systems for delivering antigens or immunomodulatory molecules to dendritic cells (DCs), T lymphocytes or both are considered effective means of eliciting adaptive immune responses and...
Citation: Genetic Vaccines and Therapy 2007 5:8 -
Tissue distribution of DNA-Hsp65/TDM-loaded PLGA microspheres and uptake by phagocytic cells
This study aimed to demonstrate that microspheres, used as delivery vehicle of DNA-Hsp65/TDM [plasmid DNA encoding heat shock protein 65 (Hsp65) coencapsulated with trehalose dimycolate (TDM) into PLGA microsp...
Citation: Genetic Vaccines and Therapy 2007 5:9 -
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo
The presence of CAR in diverse tumor types is heterogeneous with implications in tumor transduction efficiency in the context of adenoviral mediated cancer gene therapy. Preliminary studies suggest that CAR tr...
Citation: Genetic Vaccines and Therapy 2007 5:10 -
Differential intracellular distribution of DNA complexed with polyethylenimine (PEI) and PEI-polyarginine PTD influences exogenous gene expression within live COS-7 cells
Polyethylenimine (PEI) is one of the most efficient and versatile non-viral vectors available for gene delivery. Despite many advantages over viral vectors, PEI is still limited by lower transfection efficienc...
Citation: Genetic Vaccines and Therapy 2007 5:11 -
Genetic vaccine for tuberculosis (pVAXhsp65) primes neonate mice for a strong immune response at the adult stage
Vaccination of neonates is generally difficult due to the immaturity of the immune system and consequent higher susceptibility to tolerance induction. Genetic immunization has been described as an alternative ...
Citation: Genetic Vaccines and Therapy 2007 5:12 -
Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus
Adeno-associated virus (AAV) has shown great promise as a gene transfer vector. However, the incubation time needed to attain significant levels of gene expression is often too long for some clinical applicati...
Citation: Genetic Vaccines and Therapy 2007 5:13 -
ΔRR vaccination protects from KA-induced seizures and neuronal loss through ICP10PK-mediated modulation of the neuronal-microglial axis
Ischemic brain injury and epilepsy are common neurodegenerative diseases caused by excitotoxicity. Their pathogenesis includes microglial production of inflammatory cytokines. Our studies were designed to exam...
Citation: Genetic Vaccines and Therapy 2008 6:1 -
Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: A promising approach for the treatment of prostate cancer
Early prostate adenocarcinoma can be diagnosed through seric prostate-specific antigen (PSA) screenings. However, a fraction of patients progress to an incurable metastatic disease. Therefore, novel therapies ...
Citation: Genetic Vaccines and Therapy 2008 6:2 -
A DNA vaccine against tuberculosis based on the 65 kDa heat-shock protein differentially activates human macrophages and dendritic cells
A number of reports have demonstrated that rodents immunized with DNA vaccines can produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These findings have attracted ...
Citation: Genetic Vaccines and Therapy 2008 6:3 -
DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants
Tattooing is one of a number of DNA delivery methods which results in an efficient expression of an introduced gene in the epidermal and dermal layers of the skin. The tattoo procedure causes many minor mechan...
Citation: Genetic Vaccines and Therapy 2008 6:4 -
Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector
It is believed that respiratory mucosal immunization triggers more effective immune protection than parenteral immunization against respiratory infection caused by viruses and intracellular bacteria. Such unde...
Citation: Genetic Vaccines and Therapy 2008 6:5